{"product_id":"castlebiosciences-pestle-analysis","title":"Castle Biosciences PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political, economic, social, technological, legal, and environmental forces are shaping Castle Biosciences’ trajectory—our concise PESTLE snapshot highlights key risks and opportunities to inform your strategy. Buy the full analysis for a detailed, actionable report with editable charts and scenario-ready insights tailored for investors, advisors, and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Reimbursement Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare reimbursement policies heavily affect Castle Biosciences, given ~61% of melanoma and skin cancer diagnoses occur in patients 65+; Medicare covers a substantial share of DecisionDx-SCC billing, so CMS and MAC Local Coverage Determinations can materially sway revenue stability for FY2024–2025. In 2024 Castle reported 2023 revenue of $161.6M with Medicare exposure risk concentrated in older cohorts, making evidence-based advocacy and political engagement essential to preserve federal coverage for genomic tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Regulatory Oversight of LDTs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe political push for FDA oversight of LDTs has produced draft and final guidance through 2024–2025, requiring Castle Biosciences to align certain tests with medical device classifications and premarket pathways, increasing compliance costs estimated industry-wide at 10–15% of revenue for affected firms. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Spending Levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal budget allocations for cancer research—notably the NIH cancer portfolio which received about $8.5 billion in FY2024—directly affect Castle Biosciences by shaping grant availability and translational research funding.\u003c\/p\u003e\n\u003cp\u003eShifts in political priorities for national healthcare spending influence clinical adoption rates for high-end diagnostics; increased emphasis on personalized medicine (CMS coverage expansions in 2023–24) benefits genomic testing providers.\u003c\/p\u003e\n\u003cp\u003eReduced government spending or reallocations could tighten reimbursement pathways and slow market growth, while continued federal support for precision oncology offers a clear tailwind for Castle’s products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Level Healthcare Mandates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eState-level mandates shape access to Castle Biosciences genomic tests: 20 states had specific cancer screening or genetic testing directives by 2024, affecting reimbursement and utilization.\u003c\/p\u003e\n\u003cp\u003eMedicaid expansion status (39 states + DC expanded by 2024) creates a patchwork of coverage, requiring tailored market access strategies across jurisdictions.\u003c\/p\u003e\n\u003cp\u003eActive state advocacy is critical to secure inclusion of genomic assays in standard care and insurer formularies; legislative wins correlate with faster adoption and higher reimbursement rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20 states with screening\/genetic directives (2024)\u003c\/li\u003e\n\u003cli\u003e39 states + DC Medicaid expansion (2024)\u003c\/li\u003e\n\u003cli\u003eState advocacy boosts coverage and reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Expansion Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Castle Biosciences pursues international expansion, US trade relations and agreements matter—US goods exports faced 2.4% growth in 2024, but tariffs on lab equipment (up to 10–25% in some markets) and export controls on genomic technologies can raise COGS and delay market entry.\u003c\/p\u003e\n\u003cp\u003eCross-border genomic data transfer faces tightening rules (EU GDPR fines up to 4% of global turnover); political instability in target markets increases IP risk and can affect projected revenue streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariff exposure: 10–25% on lab equipment in select markets\u003c\/li\u003e\n\u003cli\u003eRegulatory risk: GDPR fines up to 4% of global turnover\u003c\/li\u003e\n\u003cli\u003eTrade growth context: US exports +2.4% in 2024\u003c\/li\u003e\n\u003cli\u003eStrategic need: assess political stability and IP enforcement before entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare, FDA LDT costs, and NIH funding to steer Castle's 2024–25 outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare reimbursement risk is material—~61% of melanoma cases are 65+ and Castle reported $161.6M revenue (2023), making CMS\/LCDs pivotal for FY2024–25; FDA LDT oversight raised compliance costs ~10–15% industry-wide; NIH cancer funding ~$8.5B (FY2024) supports translational pipelines; 39 states+DC expanded Medicaid (2024) and 20 states had genetic directives, affecting access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2023\/2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCastle Revenue\u003c\/td\u003e\n\u003ctd\u003e$161.6M (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare exposure\u003c\/td\u003e\n\u003ctd\u003e~61% melanoma in 65+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH cancer funding\u003c\/td\u003e\n\u003ctd\u003e$8.5B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid expansion\u003c\/td\u003e\n\u003ctd\u003e39 states + DC (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely impact Castle Biosciences across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section grounded in current industry data and trends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Castle Biosciences PESTLE summary that’s visually segmented for quick interpretation, easily dropped into presentations or shared across teams to streamline risk discussions and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Cost Containment Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroad efforts to cut US healthcare spending—which reached about 19.7% of GDP ($5.1 trillion) in 2023—pressure pricing for Castle Biosciences’ premium diagnostics, as payers push back on higher per-test costs. Insurers increasingly demand clinical utility data; Medicare\/Medicaid coverage decisions hinge on demonstrated downstream savings from avoided surgeries or treatments. Castle must show tests like DecisionDx-UM and DecisionDx-Melanoma produce net system savings—e.g., reduced unnecessary procedures or follow-up costs—to secure reimbursement and sustain revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Impact on Laboratory Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025 raised costs for chemical reagents, consumables and equipment maintenance by an estimated 8–12% year-over-year, increasing Castle Biosciences' per-test input costs and pressuring gross margins reported at ~60% in 2024.\u003c\/p\u003e\n\u003cp\u003eIf Castle cannot pass these higher costs to payers or improve throughput, operating margins (around 18% in 2024) may compress further; achieving 3–5% efficiency gains could offset a large portion of the impact.\u003c\/p\u003e\n\u003cp\u003eActive supply-chain management—long-term vendor contracts, bulk purchasing and dual-sourcing—has material value: industry data show multi-year contracts can lock prices and reduce input volatility by roughly 30–40% versus spot buys.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Market Access and Interest Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, the US federal funds rate at about 5.25–5.50% raises Castle Biosciences' cost of capital, making debt-funded R\u0026amp;D and acquisitions more expensive; higher borrowing costs can extend payback periods for long clinical trials. Elevated rates compress biotech valuations—Q4 2025 median EV\/Revenue for small-cap biotech hovered near 6x—reducing investor appetite and tightening Castle's liquidity and secondary financing options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Disposable Income Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic weakness reduces discretionary healthcare spending; U.S. consumer disposable personal income fell 1.3% QoQ in Q4 2023 annualized, and higher deductibles (median individual deductible ~$1,500 in 2024) can push patients to defer non-urgent dermatologic tests like Castle Biosciences’ diagnostics.\u003c\/p\u003e\n\u003cp\u003eDuring downturns dermatology visit volumes drop—Medicare Advantage data showed ~5–8% fewer outpatient dermatology visits in 2023 vs 2022—lowering diagnostic orders tied to non-emergency skin conditions.\u003c\/p\u003e\n\u003cp\u003eReduced visit volume and higher out-of-pocket exposure can compress Castle’s addressable test uptake and revenue sensitivity to macroeconomic cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDisposable income dip (Q4 2023 −1.3% QoQ) pressures out-of-pocket capacity\u003c\/li\u003e\n\u003cli\u003eMedian deductible ~$1,500 (2024) increases patient cost-share\u003c\/li\u003e\n\u003cli\u003eDermatology visits down ~5–8% in 2023 → fewer diagnostic orders\u003c\/li\u003e\n\u003cli\u003eRevenue and test volume sensitive to consumer economic health\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Payer Mix Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe balance between commercial insurance, Medicare, and self-pay creates revenue variability for Castle Biosciences; in 2024 roughly 45% of US adults had employer coverage while Medicare covered about 17% of the population, affecting reimbursement mixes for genomic tests.\u003c\/p\u003e\n\u003cp\u003eRising unemployment in 2023–2024 shifted some patients from private to public coverage, where Medicare reimbursement rates for molecular diagnostics are often lower, pressuring margins.\u003c\/p\u003e\n\u003cp\u003eCastle must adapt billing, prior authorization, and collections; in 2024 the company reported payer-denied rates around industry averages near 10–15%, underscoring the need for dynamic revenue cycle management.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMix volatility: commercial ~45%, Medicare ~17% (2024)\u003c\/li\u003e\n\u003cli\u003eUnemployment-driven shifts altered payer mix 2023–2024\u003c\/li\u003e\n\u003cli\u003eMedicare reimbursement typically lower than commercial for genomic tests\u003c\/li\u003e\n\u003cli\u003ePayer-denial rates ~10–15% (industry 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle faces margin squeeze: inflation, reimbursement and tighter biotech financing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthcare spending ~19.7% GDP ($5.1T, 2023) pressures pricing; Castle needs clinical utility to secure reimbursement. Inflation raised per-test inputs ~8–12% through 2025, squeezing gross margin ~60% (2024) and operating margin ~18% (2024). Fed funds ~5.25–5.50% (late 2025) raises cost of capital; Q4 2025 median small-cap biotech EV\/Rev ~6x, tightening financing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS healthcare %GDP (2023)\u003c\/td\u003e\n\u003ctd\u003e19.7% ($5.1T)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCastle gross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost inflation\u003c\/td\u003e\n\u003ctd\u003e8–12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (late 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmall-cap biotech EV\/Rev (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e~6x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCastle Biosciences PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Castle Biosciences PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752086057337,"sku":"castlebiosciences-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/castlebiosciences-pestle-analysis.png?v=1772237316","url":"https:\/\/growthsharematrix.com\/products\/castlebiosciences-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}